{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:02Z","timestamp":1790678582154,"version":"4.1.0"},"reference-count":69,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for \u223c15% of all leukemia. Progress of the disease from an indolent chronic phase to the more aggressive accelerated phase or blast phase (BP) occurs in a minority of cases and is associated with an accumulation of somatic mutations. We performed genetic profiling of 85 samples and transcriptome profiling of 12 samples from 59 CML patients. We identified recurrent somatic mutations in ABL1 (37%), ASXL1 (26%), RUNX1 (16%), and BCOR (16%) in the BP and observed that mutation signatures in the BP resembled those of acute myeloid leukemia (AML). We found that mutation load differed between the indolent and aggressive phases and that nonoptimal responders had more nonsilent mutations than did optimal responders at the time of diagnosis, as well as in follow-up. Using RNA sequencing, we identified other than BCR-ABL1 cancer-associated hybrid genes in 6 of the 7 BP samples. Uncovered expression alterations were in turn associated with mechanisms and pathways that could be targeted in CML management and by which somatic alterations may emerge in CML. Last, we showed the value of genetic data in CML management in a personalized medicine setting.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000943","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T12:07:23Z","timestamp":1581422843000},"page":"546-559","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":61,"title":["Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-7799","authenticated-orcid":false,"given":"Shady","family":"Adnan Awad","sequence":"first","affiliation":[{"name":"Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland;"},{"name":"Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt;"},{"name":"Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-9481","authenticated-orcid":false,"given":"Matti","family":"Kankainen","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland;"},{"name":"Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;"},{"name":"iCAN Digital Precision Cancer Medicine and"},{"name":"Department of Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8186-1707","authenticated-orcid":false,"given":"Teija","family":"Ojala","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-321X","authenticated-orcid":false,"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-4750","authenticated-orcid":false,"given":"Samuli","family":"Eldfors","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-8366","authenticated-orcid":false,"given":"Bishwa","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Kumar","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soili","family":"Kyt\u00f6l\u00e4","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Kamel","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[{"name":"iCAN Digital Precision Cancer Medicine and"},{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-5902","authenticated-orcid":false,"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;"},{"name":"iCAN Digital Precision Cancer Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland;"},{"name":"Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;"},{"name":"iCAN Digital Precision Cancer Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"issue":"10","key":"2020021112061976900_B1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2020021112061976900_B2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"9976","key":"2020021112061976900_B3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"24","key":"2020021112061976900_B4","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020021112061976900_B5","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol"},{"issue":"4","key":"2020021112061976900_B6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2020021112061976900_B7","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2020021112061976900_B8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/leu.2010.67","article-title":"BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia","volume":"24","author":"Burke","year":"2010","journal-title":"Leukemia"},{"issue":"18","key":"2020021112061976900_B9","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2020021112061976900_B10","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020021112061976900_B11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"2020021112061976900_B12","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2011-08-370981","article-title":"Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020021112061976900_B13","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2020021112061976900_B14","doi-asserted-by":"crossref","first-page":"Abstract 1473","DOI":"10.1182\/blood.V122.21.1473.1473","article-title":"Copy Number Variations and IKZF1 Mutations In Pediatric CML [abstract]","volume":"122","author":"Krumbholz","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2020021112061976900_B15","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J"},{"issue":"21","key":"2020021112061976900_B16","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2020021112061976900_B17","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2020021112061976900_B18","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"2020021112061976900_B19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020021112061976900_B20","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"20","key":"2020021112061976900_B21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020021112061976900_B22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"2020021112061976900_B23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk LymPhoma"},{"issue":"3","key":"2020021112061976900_B24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2020021112061976900_B25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3748\/wjg.v19.i8.1318","article-title":"Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor","volume":"19","author":"Lai","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"7541","key":"2020021112061976900_B26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"issue":"21","key":"2020021112061976900_B27","doi-asserted-by":"crossref","first-page":"Abstract 3727","DOI":"10.1182\/blood.V120.21.3727.3727","article-title":"Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia [abstact]","volume":"120","author":"Magistroni","year":"2012","journal-title":"Blood"},{"issue":"7463","key":"2020021112061976900_B28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer [published correction appears in Nature 2013;502:258]","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"6","key":"2020021112061976900_B29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdv110","article-title":"A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia","volume":"26","author":"Korfi","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"2020021112061976900_B30","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res"},{"issue":"14","key":"2020021112061976900_B31","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/onc.2012.203","article-title":"Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias","volume":"32","author":"Tobin","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"2020021112061976900_B32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00439-008-0542-4","article-title":"Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?","volume":"124","author":"Wimmer","year":"2008","journal-title":"Hum Genet"},{"issue":"14","key":"2020021112061976900_B33","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020021112061976900_B34","doi-asserted-by":"crossref","first-page":"e79118","DOI":"10.1371\/journal.pone.0079118","article-title":"Discovering transcription and splicing networks in myelodysplastic syndromes","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2020021112061976900_B35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ng.2874","article-title":"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","volume":"46","author":"Papaemmanuil","year":"2014","journal-title":"Nat Genet"},{"key":"2020021112061976900_B36","doi-asserted-by":"crossref","first-page":"Abstract 4257","DOI":"10.1182\/blood-2018-99-111602","article-title":"RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities [abstract]","volume":"132","author":"Awad","year":"2018","journal-title":"Blood"},{"issue":"7696","key":"2020021112061976900_B37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"issue":"18","key":"2020021112061976900_B38","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","article-title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders","volume":"122","author":"Damm","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2020021112061976900_B39","doi-asserted-by":"crossref","first-page":"e0189102","DOI":"10.1371\/journal.pone.0189102","article-title":"BRD3\/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells","volume":"12","author":"Carretta","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"2020021112061976900_B40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ng.2983","article-title":"Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer","volume":"46","author":"Wang","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2020021112061976900_B41","first-page":"201","article-title":"Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis","volume":"12","author":"Waerner","year":"2001","journal-title":"Cell Growth Differ"},{"key":"2020021112061976900_B42","first-page":"Abstract 43","article-title":"SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia [abstract]","volume":"130","author":"Mancini","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020021112061976900_B43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med"},{"issue":"6","key":"2020021112061976900_B44","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"2020021112061976900_B45","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2020021112061976900_B46","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"key":"2020021112061976900_B47","first-page":"Abstract 1585","article-title":"Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment [abstract]","volume":"130","author":"Baer","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020021112061976900_B48","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"2020021112061976900_B49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5732\/cjc.014.10146","article-title":"Receptor-type protein tyrosine phosphatases in cancer","volume":"34","author":"Du","year":"2015","journal-title":"Chin J Cancer"},{"issue":"3","key":"2020021112061976900_B50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1073\/pnas.1319551111","article-title":"Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer","volume":"111","author":"Lui","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"2020021112061976900_B51","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1158\/0008-5472.CAN-10-0258","article-title":"Protein tyrosine phosphatase receptor type gamma is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia","volume":"70","author":"Della Peruta","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"2020021112061976900_B52","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ajh.24710","article-title":"Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm","volume":"92","author":"Salem","year":"2017","journal-title":"Am J Hematol"},{"key":"2020021112061976900_B53","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat Commun"},{"issue":"37","key":"2020021112061976900_B54","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1038\/onc.2014.406","article-title":"The landscape and therapeutic relevance of cancer-associated transcript fusions","volume":"34","author":"Yoshihara","year":"2015","journal-title":"Oncogene"},{"issue":"12","key":"2020021112061976900_B55","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/cam4.1187","article-title":"Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib","volume":"6","author":"Avil\u00e9s-V\u00e1zquez","year":"2017","journal-title":"Cancer Med"},{"issue":"17","key":"2020021112061976900_B56","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020021112061976900_B57","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1002\/jcp.26599","article-title":"CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells","volume":"233","author":"Huang","year":"2018","journal-title":"J Cell Physiol"},{"issue":"8","key":"2020021112061976900_B58","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1158\/1078-0432.CCR-05-2552","article-title":"Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia","volume":"12","author":"Steinbach","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2020021112061976900_B59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2017.08.034","article-title":"Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions","volume":"408","author":"Sadras","year":"2017","journal-title":"Cancer Lett"},{"issue":"1","key":"2020021112061976900_B60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/hmg\/ddq451","article-title":"Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery","volume":"20","author":"Ha","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"7","key":"2020021112061976900_B61","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1172\/JCI76099","article-title":"Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage","volume":"125","author":"Barrett","year":"2015","journal-title":"J Clin Invest"},{"key":"2020021112061976900_B62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2018.04.001","article-title":"Acetylation of oxidized base repair-initiating NEIL1 DNA glycosylase required for chromatin-bound repair complex formation in the human genome increases cellular resistance to oxidative stress","volume":"66-67","author":"Sengupta","year":"2018","journal-title":"DNA RePair (Amst)"},{"issue":"2","key":"2020021112061976900_B63","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3324\/haematol.2017.170431","article-title":"WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia","volume":"103","author":"Bordin","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2020021112061976900_B64","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mc.22248","article-title":"Wilms\u2019 tumor gene WT1 promotes homologous recombination-mediated DNA damage repair","volume":"54","author":"Oji","year":"2015","journal-title":"Mol Carcinog"},{"issue":"5","key":"2020021112061976900_B65","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/leu.2011.322","article-title":"Silencing of ETV6\/RUNX1 abrogates PI3K\/AKT\/mTOR signaling and impairs reconstitution of leukemia in xenografts","volume":"26","author":"Fuka","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"2020021112061976900_B66","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jcb.25802","article-title":"Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis","volume":"118","author":"Kilbey","year":"2017","journal-title":"J Cell Biochem"},{"issue":"5","key":"2020021112061976900_B67","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2006.06372.x","article-title":"t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)\/VEGF receptor type2 pathway and phosphorylation of Akt","volume":"135","author":"Imai","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021112061976900_B68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-011-1396-3","article-title":"FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells [published correction appears in Breast Cancer Res Treat. 2016;156:609-610]","volume":"131","author":"Du","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2020021112061976900_B69","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.cell.2008.12.043","article-title":"Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells","volume":"136","author":"Ezhkova","year":"2009","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/546\/1634302\/advancesadv2019000943.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/546\/1634302\/advancesadv2019000943.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T12:08:31Z","timestamp":1581422911000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/3\/546\/441054\/Mutation-accumulation-in-cancer-genes-relates-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000943","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}